Nice & Green

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.

Lucibel is a French company that specializes in designing and manufacturing advanced lighting products and solutions utilizing LED technology. Committed to sustainability and efficiency, Lucibel's offerings are not only energy-efficient but also integrate smart features that facilitate remote management. Their innovative lighting solutions enable real-time control and measurement, allowing light to interact dynamically with its environment. Additionally, Lucibel's technology supports new forms of data transmission and enhances user well-being, positioning the company at the forefront of the digital lighting era.

LIDDS AB is a pharmaceutical company based in Uppsala, Sweden, focused on developing injectable drugs for cancer and other diseases. Utilizing its proprietary NanoZolid® technology, LIDDS addresses key challenges in drug delivery, enhancing patient quality of life by enabling controlled, long-term release of medications for up to six months. The company is working on various drug candidates, including NZ-2HOF for prostate cancer, NZ-DTX for multiple cancer types, NZ-DOX for solid tumors, and several immunotherapy agents aimed at improving cancer treatment outcomes. LIDDS is committed to addressing medical needs through innovative drug delivery solutions.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Endurance Motive design and implementation of sustainable energy solutions for industrial vehicles, nautical vessels and public transport. Discover the advantages of switching to Lithium.

EEMS Italia is a semiconductor manufacturer that specializes in producing photovoltaic panels and developing semiconductor memories. With operations in both China and Italy, the company aims to enhance its role in the energy sector and the Green Economy. EEMS Italia plans to begin as a wholesaler in the energy transition sector, with the goal of evolving into a multi-utility operator. The company is committed to promoting and facilitating the shift towards cleaner and more sustainable energy sources.

Marinomed Biotech AG is a biopharmaceutical company based in Vienna, Austria, specializing in the development of innovative therapies for respiratory and ophthalmological diseases. Founded in 2006, the company operates primarily through two technology platforms: Marinosolv and Carragelose. Marinosolv enables the creation of stable aqueous formulations for poorly soluble compounds, enhancing their bioavailability and therapeutic efficacy, while Carragelose offers antiviral solutions aimed at respiratory viruses. Marinomed's product portfolio includes nasal sprays, throat sprays, and lozenges designed to block viruses and alleviate symptoms associated with conditions such as cough, cold, influenza, and allergic rhinitis. The company collaborates with partners to market its products globally, focusing on improving treatment options for patients with sensitive tissues in the nose and eyes.

Tessellis S.p.A. is an Italian telecommunications company based in Sa Illetta, founded in 1998. It provides a variety of Internet services, including broadband and narrowband access, as well as voice services. The company also specializes in more advanced telecommunications products and offers portal and mobile telephone services. Tessellis operates through several segments, including Access, which encompasses both business-to-consumer and business-to-business connectivity, as well as Media & Advertising and Corporate services. Through its diverse offerings, Tessellis aims to meet the needs of both individual and corporate clients in the rapidly evolving telecommunications landscape.

Napster is a provider of subscription-based digital music services that offers users ad-free access to millions of songs. The platform allows members to enjoy unlimited on-demand music from various devices, including laptops, smartphones, and Internet-connected home stereo systems. In addition to music, Napster provides features such as playlists, reviews, and radio stations, enhancing the overall music experience. The service is accessible online and is available in several countries, including the United States, Canada, Germany, and the United Kingdom. As a wholly-owned subsidiary of Best Buy, Napster focuses on creating engaging ways for users to discover, share, and enjoy music anytime and anywhere.

MelodyVR is a pioneering Virtual Reality music platform operating in the US, UK, and Europe. It holds the distinction of being the only licensed VR music platform globally, having established partnerships with all major record labels, including Universal Music Group, Sony Music Entertainment, Warner Music Group, and Roc Nation. The company has created a comprehensive end-to-end process that facilitates the entry of prominent artists into the realm of virtual reality. MelodyVR boasts the world's largest library of interactive music content, collaborating with over 650 international artists. Users are offered a unique experience with multiple perspectives, ranging from being immersed in the crowd to enjoying close-up views of performances. In addition to a vast collection of recorded shows, MelodyVR also live streams concerts in virtual reality, having partnered with several major venues in the UK. The company is based in Hitchin, United Kingdom, and has developed proprietary technology that enables the transformation of recorded material into immersive 360-degree panoramic video content.

Rapid Nutrition is a natural healthcare company focused on the development and distribution of premium, science-based health and wellness products. The company specializes in producing natural nutrition solutions, offering services that encompass research, development, and production of evidence-based nutrition. Its flagship brands include SystemLS, Leisa's Secret, and The Plant-Based Bundle, each designed to cater to various health and wellness needs. Rapid Nutrition emphasizes the importance of quality and scientific backing in its product offerings.

cyan Security Group GmbH is a Vienna-based company that specializes in the development and distribution of mobile security solutions. With over 25 years of experience in the IT security field, cyan provides customized solutions tailored to various business segments. The company operates a research and development center in Brno, Czech Republic, which fosters collaboration with universities, international institutes, and financial organizations. This close cooperation enables cyan to identify emerging trends and technological advancements, ensuring the integration of cutting-edge features into its products. As a subsidiary of cyan AG, the company leverages its parent organization's resources and expertise to enhance its offerings in the security sector.

FacePhi is the leading Spanish company in biometric solutions for identity verification, specialized in facial recognition systems, digital onboarding and safe work environments. Based in Alicante and operating worldwide, the company has a presence in more than 25 countries, has performed more than 1 trillion authentications, 21 million access programs and has a strong presence in the banking sector. The drive of biometrics to improve customer experience and protect data from citizens and entities is the hallmark of the firm.

Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Bublar Group is a Swedish company based in Stockholm that focuses on the development of mobile gaming through the integration of augmented reality (AR) and virtual reality (VR) technologies. The company combines smartphone capabilities with advanced 3D graphics to create engaging and interactive experiences for users, allowing them to generate personal real-time 3D objects that can be seamlessly integrated into their real-world environments. With a team experienced in simulation systems, eye-tracking, and location-based services, Bublar aims to revolutionize how users interact with digital content. Its innovative approach not only enhances mobile gaming but also positions the company at the forefront of the AR and VR industries.

Artificial Solutions International AB specializes in providing a conversational AI platform that enables users to interact with applications, websites, and devices using natural language through various inputs such as voice, text, touch, or gesture. Their Teneo platform facilitates collaboration between business users and developers to create sophisticated applications that support 35 languages and operate across multiple platforms and channels. The platform not only enhances user communication but also integrates the analysis of conversational data, offering valuable insights into customer behavior and preferences. Artificial Solutions serves a diverse range of industries, including banking, automotive, retail, telecommunications, energy, travel, and media, and is headquartered in Stockholm, Sweden. Founded in 2001, the company is recognized as a leader in enterprise-strength conversational AI.

FacePhi is the leading Spanish company in biometric solutions for identity verification, specialized in facial recognition systems, digital onboarding and safe work environments. Based in Alicante and operating worldwide, the company has a presence in more than 25 countries, has performed more than 1 trillion authentications, 21 million access programs and has a strong presence in the banking sector. The drive of biometrics to improve customer experience and protect data from citizens and entities is the hallmark of the firm.

Itway S.p.A is an Italy-based company operating in the information technology sector, specializing in cyber security solutions. The company focuses on the distribution and integration of products and services aimed at enhancing the logical security of IT systems. Itway generates most of its revenue from the Value Added Distribution segment, which includes services related to Value Added Resellers and Value Added Services. In addition to its distribution activities, Itway also engages in the production of software technologies for e-business and offers professional services as a system integrator, facilitating the centralization of applications for its clients.

WISeKey is a global cybersecurity company specializing in integrated security solutions for the Internet of Things (IoT) and digital identity ecosystems. Headquartered in Switzerland, the company leverages its patented cryptographic Root of Trust (RoT) to provide secure authentication and identification across both physical and virtual environments. WISeKey's offerings include a range of semiconductor chips, cybersecurity software, and managed public key infrastructure (PKI) services, all designed to protect users, devices, data, and transactions in an increasingly interconnected world. The company operates primarily through two business segments: the IoT segment, which focuses on the sale of secure semiconductor chips and is the main revenue driver, and the mPKI segment, which generates revenue through digital certificates. WISeKey's comprehensive solutions address significant gaps in cybersecurity and data protection, enabling clients to navigate the evolving landscape of digital devices without compromising their security.

Moberg Derma is a Swedish pharmaceutical company that focuses on commercializing proprietary, acquired, and licensed products in the global market. The company aims to deliver value to patients, healthcare professionals, and stakeholders by providing products based on proven compounds that demonstrate improved efficacy, reduced side effects, or enhanced usability. While Moberg Derma initially concentrated on treating skin diseases, it is now expanding its product offerings to include other therapeutic areas. The company markets over-the-counter brands in the United States and distributes its products in more than 35 countries worldwide.

FacePhi is the leading Spanish company in biometric solutions for identity verification, specialized in facial recognition systems, digital onboarding and safe work environments. Based in Alicante and operating worldwide, the company has a presence in more than 25 countries, has performed more than 1 trillion authentications, 21 million access programs and has a strong presence in the banking sector. The drive of biometrics to improve customer experience and protect data from citizens and entities is the hallmark of the firm.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Theraclion is a French company founded in 2004 that specializes in high-tech medical equipment utilizing high-intensity focused ultrasound (HIFU) technology. The company has developed innovative echotherapy solutions that integrate HIFU therapy with ultrasound imaging to non-invasively target and treat benign tumors and varicose veins. Its flagship product, Echopulse®, is designed for the non-invasive treatment of breast fibroadenomas and benign thyroid nodules, while the SONOVEIN® system specifically addresses varicose veins in the lower limbs. Theraclion's focus on ultrasound for therapeutic applications positions it as a pioneer in this field, offering advanced solutions for patients requiring non-invasive treatment options.

Implanet S.A. is a medical device company based in Martillac, France, specializing in the design, manufacture, and sale of orthopedic implants and devices. Founded in 2006, the company offers a range of products for orthopedic surgery, including spinal systems, knee prostheses, and arthroscopy tools. Notable offerings include the Jazz series of posterior fixation systems and the Madison knee prosthesis, designed for conventional surgical techniques. Implanet aims to provide high-quality, innovative solutions that enhance the productivity of healthcare professionals while addressing the need for cost-effective healthcare. The company primarily serves markets in France, the United States, Brazil, and internationally, ensuring that its products meet the evolving needs of orthopedic care providers.

SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Amoeba is a France-based company dedicated to the development, production, and commercialization of green biocide water treatment chemicals for the industrial sector. Its primary product, BIOMEBA, utilizes the biocidal properties of Willaertia magna to effectively address bacterial risks in cooling towers. By focusing on environmentally friendly solutions, Amoeba aims to provide sustainable alternatives in water treatment, enhancing safety and efficiency in industrial applications.

Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.

Saniona is a pharmaceutical company dedicated to researching and developing innovative treatments for various diseases, including those affecting the central nervous system, autoimmune disorders, metabolic conditions, and pain management. The company specializes in the development of highly selective ion channel modulators, employing a technology platform that targets GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. Its most advanced product candidate, Tesomet, is currently in mid-stage clinical trials for rare eating disorders. Additionally, Saniona is advancing two other product candidates: SAN711, which has successfully completed a Phase 1 clinical trial for neuropathic pain conditions, and SAN903, which is preparing to enter Phase 1 trials for inflammatory and fibrotic disorders. The company is committed to leveraging its expertise in ion channel modulation to create effective new medicines.

Oryzon Genomics S.A. is a clinical phase biopharmaceutical company focused on the discovery and development of epigenetics-based therapeutics aimed at treating cancer and central nervous system (CNS) disorders. The company is advancing its clinical pipeline with two key compounds currently in Phase II trials: iadademstat, a selective LSD1 inhibitor designed for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor targeting neurological diseases. Additionally, Oryzon is developing ORY-3001, another LSD1 inhibitor that is in preclinical stages for non-oncological conditions. Founded in 2000 and headquartered in Cornellà de Llobregat, Spain, Oryzon Genomics utilizes its epigenetic platform to identify and validate biomarkers and therapeutic targets, facilitating the creation of advanced and personalized therapies.